Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 49NIH 7NETWORK 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 47Head & Neck 28Thoracic 26Gastrointestinal 20Genitourinary 10Breast 8Lymphoid 6Sarcoma 5Other 5Tumor-Agnostic 3Other solid neoplasm 2Other hematologic neoplasm 2Plasma cell 1Myeloid 1Gynecologic 1Dermatologic 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Graft vs Host Disease 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Azacitidine 68nilotinib 50Imatinib Mesylate 50ruxolitinib 42Dasatinib 25venetoclax 22Decitabine 20bosutinib 18asciminib 17Cytarabine 15ponatinib 10decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 9fludarabine 8Hydroxyurea 8navitoclax 6ON 01910 6sabatolimab 5pevonedistat 5mocetinostat 5luspatercept 5itacitinib 5imetelstat 5givinostat hydrochloride 5givinostat 5fludarabine phosphate 5avapritinib 5Mycophenolic Acid 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Radiotherapy × Myeloid × Clear all
NCT00081055 2014-12-04

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Mesoblast, Ltd.

Phase 2 Withdrawn
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡